– USA, MA – BYOMass, Inc., a biotech company developing selective TGF-β superfamily therapeutics, today announced the appointment of Dr. Declan Doogan (M.D.), and Dr. Stephen Hoffman (M.D., Ph.D.) to its Board of Directors.
“As biotech cofounders, executive leaders, and expert drug developers, Drs. Doogan and Hoffman have extensive experience in building biotech companies, guiding innovation, and developing therapies from early-stage research through commercialization,” said Founder and CEO, Dr. Margaret Jackson. “Their significant insights will be invaluable to us as we advance novel biologics and small molecules to target the TGF-β superfamily, a significant biological pathway involved in numerous diseases and disorders without effective therapies.”
About Dr. Declan Doogan
Dr. Doogan has more than 30 years of experience in the global pharmaceutical industry and is the CMO and Co-founder of Juvenescence. In addition to his role at Juvenescence, Dr. Doogan is the Chairman and Co-founder of Biohaven Pharmaceuticals, Portage Biotech, and PH Precision Med, and a visiting professor at Glasgow University. Previously, Dr. Doogan was Head of Worldwide Drug Development at Pfizer, where he worked in the US, UK, and Japan. Previously, he was also Head of R&D at Amarin Corporation.
“The members of the TGF-β superfamily are master regulators of a wide range of physiological processes, including tissue morphogenesis, tissue repair, hematopoiesis, immunoregulation, and reproductive function,” said Dr. Doogan. “With the safety concerns involved in inhibiting TGF-β directly or blocking pathway receptors, the team at BYOMass has established a unique approach to selectively targeting specific members and pathways within the TGF-β superfamily that has the potential to treat a range of diseases and disorders.”
Dr. Doogan earned his M.D. from Glasgow University, and he is a Fellow of the Royal College of Physicians and Surgeons of Glasgow.
About Dr. Stephen Hoffman
Dr. Hoffman has more than 30 years of experience in founding, leading, and advising biotech companies advancing innovative therapeutic pipelines. Dr. Hoffman most recently served as CEO of Aerpio Pharmaceuticals and before that was a senior advisor to PDL BioPharma, a General Partner at TVM Capital, and a Managing Director at Skyline Ventures. Before his positions in venture capital, Dr. Hoffman served as President, CEO, and a member of the board of directors of Allos Therapeutics, where he remained as Chairman of the Board until it was acquired by Spectrum Pharmaceuticals. Dr. Hoffman currently serves on the Boards of Directors of AcelRx Pharmaceuticals, Dicerna Pharmaceuticals, Danforth Advisors, and Apic Bio.
“BYOMass has internally developed a pathway-driven pipeline of novel biologics and first-in-class small molecules selective targeting TGF-β superfamily members that have the potential to offer safe and effective therapeutics for orphan and common diseases of high unmet medical need,” said Dr. Hoffman. “Furthermore, the team is pioneering a precision medicine approach to clinical development by identifying patient populations where specific TGF-β superfamily members play a major role in their disease.”
About BYOMass
BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need. Selectively targeting specific members and pathways within the TGF-β superfamily has the potential to be a meaningful class of therapeutics within oncology, inflammatory/immune, fibrotic, and metabolic diseases.
For more information: https://byomasstx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
